An observational study in Patient With a Prescribed Endotest and Endometriosis (Diagnosis), sponsored by ZIWIG. Recruiting at 7 sites in France. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by ZIWIG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.
Among the 128 studies in Endometriosis with a site in France, this one is the 2nd largest by planned enrollment of the 58 observational ones that give a count, is one of 15 that started in 2026, is one of 58 observational ones, reaches primary completion later than 50 of the 55 other live ones, and was the 121st registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Limoges · Sites in France
Ages 18–50 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Women only
Elsan · Sites in France
Ages 18–45 · Women only
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–40 · Women only
University Hospital, Toulouse · Sites in France
Ages 18+ · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 43 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 6 · Phase 4 1
First in 1990; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 132 across 351 observational studies indexed under Endometriosis.
Median enrollment 91 across the 70 interventional studies, 133 across the 58 observational. Of the 54 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 128 have an industry lead sponsor. The 10 most frequent:
ZIWIG is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
ZIWIG has 6 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
21 of the studies in Endometriosis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973603Institut National de la Santé Et de la Recherche Médicale, FranceExposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis Cohort | 2026-12 |
| NCT04704115University Hospital, LilleThe Therapy of Large Endometrioma | 2026-12 |
| NCT06392997ZIWIGEvaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology | 2026-12 |
| NCT07864883University Hospital, Strasbourg, France3D Modeling of Deep Endometriosis From Pelvic MRI | 2026-12-27 |
| NCT04554602Assistance Publique - Hôpitaux de ParisFusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 128 studies in Endometriosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ziwig Endotest® ('Endotest') is marketed in several countries, including Switzerland, which was the first country to make it available in 2022. Since February 2025, several French clinical investigation sites have been offering Endotest, developed by Ziwig, under the innovation funding. Initially, this innovation funding enabled 2,500 patients to be included in a clinical trial (ENDOBEST: ID-RCB 2024-A02092-45). Since the end of December 2025, it has been expanded and now covers a further 22,500 patients whose are not included in the trial. This medical device is based on Next-Generation Sequencing combined with analytical algorithms and enables the identification of endometriosis from a saliva sample. This non-invasive test aims to improve patient care by reducing diagnostic delays and guiding treatment strategies.
Despite the available data on its diagnostic performance, the impact of Endotest on patients' quality of life, their emotional experience, their coping strategies, and their care pathways remains insufficiently documented. Indeed, the Endotest result (positive or negative) can significantly influence these various aspects. This cohort study aims to assess the impact of Endotest on patients' quality of life, primarily using validated self-report questionnaires and clinical data from medical records. By including a large sample of patients, this study aims to provide robust and generalisable data that will be useful for clinicians and patients themselves.
Patient with endometriosis for whom an Endotest is prescribed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
for the use of Endotest:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Questionnaire
EHP 5+6, RAND-36 et 6 and 12 months follow-up visits
To assess the impact of Endotest on quality of life and identify the factors associated with quality of life.
Endometriosis-specific quality of life score on the EHP-5 + 6 questionnaire (Endometriosis Health Profile - 11 items). Score goes from 0 to 44. Higher the score is, worse the outcome is.
Time frame: Day 1, 6 months and 12 months.
To assess the impact of Endotest on quality of life and identify the factors associated with quality of life.
Score for each of the 8 dimensions of quality of life on the RAND-36 questionnaire (declined version of the 36-Item Short Form Survey (SF-36)) Score goes from 0 to 100 for each ones of the 8 dimensions. Higher the score is, better the outocome is.
Time frame: Day 1, 6 months and 12 months
To assess the impact of Endotest on quality of life and identify the factors associated with quality of life.
Factors associated with the level of endometriosis-specific quality of life (EHP-5+6 (Endometriosis Health Profile - 11 items)) at 6 months. Score goes from 0 to 44. Higher the score is, worse the outcome is.
Time frame: 6 months
To assess the impact of Endotest on quality of life and identify the factors associated with quality of life.
Factors associated with the level of each of the 8 dimensions of general quality of life (RAND-36 (declined version of the 36-Item Short Form Survey (SF-36)) at 6 months. Score goes from 0 to 100 for each ones of the 8 dimensions. Higher the score is, better the outocome is.
Time frame: 6 months
Describe the impact of Endotest on adaptation strategies.
Brief-COPE score (Brief Coping Orientation to Problems Experienced) Score goes from 1 to 4 for the 3 subscales (Problem Focussed, Emotion Focussed, Avoidant) There is no direct correlation between higher/lower scores and better/worse outcomes
Time frame: 6 months
Describe the impact of Endotest on the assisted reproductive technology (ART) journey (including infertility assessment and fertility preservation).
Number of patients starting an assisted reproductive technology (ART) treatment programme
Time frame: Through study completion, an average of 1 year
Describe the impact of Endotest on the assisted reproductive technology (ART) journey (including infertility assessment and fertility preservation).
Number of patients for whom the ART treatment plan is amended (e.g. switching from intrauterine insemination to IVF, surgery)
Time frame: Through study completion, an average of 1 year
Describe the impact of Endotest's results immediately following the announcement.
Personalised questionnaire on immediate emotional reactions
Time frame: 1 month
Describe the impact of Endotest on patient care: tests, treatments, and additional procedures (e.g., laparoscopy).
Number and type of additional tests or procedures performed (ultrasound, MRI, laparoscopy, etc.).
Time frame: Through study completion, an average of 1 year
Describe the impact of Endotest on patient care: tests, treatments, and additional procedures (e.g., laparoscopy).
Initiation or modification of treatments (hormonal, pain relievers, etc.).
Time frame: Through study completion, an average of 1 year
To assess the impact of Endotest on anxiety levels.
Visual Analog Scale Anxiety Score Score goes from 0 to 100 Lower the score is, better the outcome is
Time frame: 1 month
Compare the care provided to patients with a positive Endotest result across participating countries.
Type of coverage and waiting period
Time frame: Through study completion, an average of 1 year
Compare pelvic sensitivity based on Endotest results
Convergences Score for Pelvic-Perineal Pain Score goes from 0 to 10 Lower the score is, better the outcome is.
Time frame: Day 1 and 12 months
Started May 2026 (actual). Primary completion is estimated for Jul 2029, 38 months after the start.
Of 185 observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 38 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ZIWIG